Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

Chronic myeloid leukemia was the first haematological neoplasia that benefited from a targeted therapy with imatinib nearly 15 years ago. Since then, several studies have investigated the role of genes, their variants (i.e., polymorphisms) and their encoded proteins in the pharmacokinetics and pharm...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Mol Sci
Autori principali: Polillo, Marialuisa, Galimberti, Sara, Baratè, Claudia, Petrini, Mario, Danesi, Romano, Di Paolo, Antonello
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2015
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4613337/
https://ncbi.nlm.nih.gov/pubmed/26402671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms160922811
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi